Medical Information

Erdafitinib is an FGFR kinase inhibitor used to treat specific types of advanced urothelial carcinoma. Attention should be paid to adverse reactions such as eye toxicity and hyperphosphatemia when using it. For special populations, medication should be adjusted according to pregnancy, lactation, liver and kidney function, and other conditions.

1. Precautions

(1) Eye toxicity: May cause central serous retinopathy or retinal detachment. Ophthalmic examination is required before use, and visual acuity changes should be monitored monthly during treatment.

(2) Hyperphosphatemia: A common adverse reaction that requires regular monitoring of blood phosphorus levels, and the use of phosphorus lowering drugs or adjustment of dosage if necessary.

(3) Embryotoxicity: Based on animal research, it may cause harm to the fetus, and patients of childbearing age need to take effective contraceptive measures.

2. Medication for special populations

(1) Pregnancy period: There is no data on the use of drugs by pregnant women. Animal studies have shown embryotoxicity, and pregnancy should be avoided during treatment and one month after discontinuation of medication.

(2) Breastfeeding period: It is unknown whether the medication has entered human milk. It is recommended to stop breastfeeding during the treatment period and within one month after the last administration.

(3) Reproductive potential population: Women need to use contraception during treatment and within one month after discontinuing medication, while men need to use contraception during treatment and within three months after discontinuing medication.

(4) Pediatric patients: Safety and efficacy have not been established and are not recommended for use.

(5) Elderly patients: Patients over 65 years old do not need to adjust the dosage, but adverse reactions need to be closely monitored.

(6) Liver function impairment: Moderate impairment should be reduced by 50%, and severe impairment should be avoided.

(7) Renal function impairment: Mild to moderate impairment does not require adjustment, while severe impairment requires careful use.

3. Drug interactions

(1) CYP3A4 inhibitors: may increase exposure to edatinib, and should be avoided in combination with potent inhibitors.

(2) CYP3A4 inducer: May reduce the efficacy of Edatinib, avoid using strong inducers in combination.

(3) P-gp substrate: may increase the concentration of P-gp substrate drugs, caution should be exercised when combining narrow therapeutic window drugs.